CA2385722A1 - Utilisation de csaids contre l'infection par rhinovirus - Google Patents

Utilisation de csaids contre l'infection par rhinovirus Download PDF

Info

Publication number
CA2385722A1
CA2385722A1 CA002385722A CA2385722A CA2385722A1 CA 2385722 A1 CA2385722 A1 CA 2385722A1 CA 002385722 A CA002385722 A CA 002385722A CA 2385722 A CA2385722 A CA 2385722A CA 2385722 A1 CA2385722 A1 CA 2385722A1
Authority
CA
Canada
Prior art keywords
inhibitor
imidazole
fluorophenyl
therapeutic agent
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002385722A
Other languages
English (en)
Inventor
Sandra D. Griego
Susan B. Dillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2385722A1 publication Critical patent/CA2385722A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de l'inhibiteur CSBP/p38 dans le traitement des symptômes du rhume banal et de l'exacerbation des symptômes e cette affection chez l'homme.
CA002385722A 1999-09-17 2000-09-15 Utilisation de csaids contre l'infection par rhinovirus Abandoned CA2385722A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15449499P 1999-09-17 1999-09-17
US60/154,494 1999-09-17
PCT/US2000/025386 WO2001019322A2 (fr) 1999-09-17 2000-09-15 Utilisation de csaids contre l'infection par rhinovirus

Publications (1)

Publication Number Publication Date
CA2385722A1 true CA2385722A1 (fr) 2001-03-22

Family

ID=22551566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002385722A Abandoned CA2385722A1 (fr) 1999-09-17 2000-09-15 Utilisation de csaids contre l'infection par rhinovirus

Country Status (17)

Country Link
EP (1) EP1223924A4 (fr)
JP (1) JP2003516314A (fr)
KR (1) KR20020032591A (fr)
CN (1) CN1382044A (fr)
AR (1) AR025691A1 (fr)
AU (1) AU7584500A (fr)
BR (1) BR0014041A (fr)
CA (1) CA2385722A1 (fr)
CO (1) CO5200855A1 (fr)
CZ (1) CZ2002939A3 (fr)
HU (1) HUP0204333A3 (fr)
IL (1) IL148329A0 (fr)
NO (1) NO20021301L (fr)
PL (1) PL363116A1 (fr)
TR (1) TR200200673T2 (fr)
WO (1) WO2001019322A2 (fr)
ZA (1) ZA200202060B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
AU2002248269A1 (en) * 2000-10-19 2002-08-12 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of inflammation-enhanced cough
EP1333833B1 (fr) 2000-10-23 2011-08-24 GlaxoSmithKline LLC Nouveau composé 8H-pyrido[2,3-d]pyrimidin-7-one trisubstituté pour le traitement des maladies faisant intervenir les kinases CSBP/p38
AU2003230692A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of map kinase inhibitors
BR0309009A (pt) * 2002-04-05 2005-03-22 Boehringer Ingelheim Pharma Método para o tratamento de hipersecreção de muco
DE60310730T2 (de) * 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
JP4593953B2 (ja) * 2004-03-30 2010-12-08 杏林製薬株式会社 ライノウイルス感染症の予防薬
MX2007001561A (es) * 2004-08-04 2007-04-16 Schering Corp Formulacion farmaceutica que comprende pleconaril para tratamiento de enfermedades de vias aereas.
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
JP5558458B2 (ja) * 2008-03-20 2014-07-23 タノメド・アクチボラゲット 普通感冒の治療用の医薬の製造における物質の使用
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
CN102573886A (zh) * 2009-09-17 2012-07-11 相互制药公司 用抗病毒剂治疗哮喘的方法
GB201010193D0 (en) 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
US11730760B2 (en) 2011-04-01 2023-08-22 The Bioregentech Institute, Inc. Laser assisted wound healing protocol and system
US11389663B2 (en) 2011-04-01 2022-07-19 Bioregentech, Inc. Laser assisted wound healing protocol and system
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
WO2019071147A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Inhibiteurs de la kinase p38 réduisant l'expression du gène dux4 et des gènes aval pour le traitement de la fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
GB201721793D0 (en) * 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza
WO2021216754A1 (fr) * 2020-04-21 2021-10-28 Spring Discovery, Inc. Utilisation d'inhibiteurs de p38 mapk pour la prévention et le traitement du vieillissement et de troubles liés au vieillissement et pour renforcer un système immunitaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927216A (en) * 1971-06-01 1975-12-16 Icn Pharmaceuticals 1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
US6469018B1 (en) * 1999-01-08 2002-10-22 Smithkline Beecham Corporation Compounds

Also Published As

Publication number Publication date
NO20021301D0 (no) 2002-03-15
KR20020032591A (ko) 2002-05-03
HUP0204333A2 (en) 2003-05-28
WO2001019322A3 (fr) 2001-10-04
EP1223924A4 (fr) 2004-07-14
TR200200673T2 (tr) 2002-12-23
JP2003516314A (ja) 2003-05-13
CZ2002939A3 (cs) 2002-11-13
WO2001019322A2 (fr) 2001-03-22
HUP0204333A3 (en) 2004-07-28
PL363116A1 (en) 2004-11-15
AU7584500A (en) 2001-04-17
BR0014041A (pt) 2003-07-15
NO20021301L (no) 2002-05-16
CO5200855A1 (es) 2002-09-27
ZA200202060B (en) 2003-05-28
EP1223924A2 (fr) 2002-07-24
IL148329A0 (en) 2002-09-12
CN1382044A (zh) 2002-11-27
AR025691A1 (es) 2002-12-11

Similar Documents

Publication Publication Date Title
CA2385722A1 (fr) Utilisation de csaids contre l'infection par rhinovirus
US9993478B2 (en) 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors
JP6620324B2 (ja) グルタルイミド誘導体、その使用、それに基づいた医薬組成物及びグルタルイミド誘導体を製造するための方法
US9168269B2 (en) Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
US20110105423A1 (en) Compounds that modulate negative-sense, single-stranded rna virus replication and uses thereof
JP2014505076A (ja) 抗ウイルス剤としてのｍＴＯＲキナーゼの阻害剤
ES2241675T3 (es) Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de cspb/p38 quinasa.
JP2004530648A (ja) 炎症により促進される咳の治療のためのｐ３８阻害剤の使用
US20230210848A1 (en) Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug
US6982270B1 (en) 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US9096585B2 (en) Antiviral compounds and uses thereof
ES2230171T3 (es) Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
WO2013029006A1 (fr) Thérapies contre le virus de la dengue et le virus de la fièvre jaune
US6759410B1 (en) 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
WO2002032862A2 (fr) Utilisation d'inhibiteurs de p38 pour le traitement de troubles dus a l'inhalation du tabac
WO2014031571A1 (fr) Traitement d'infections virales
CN116406273A (zh) 氮卓斯汀用作抗病毒治疗
US20230226056A1 (en) Compatible solutes for preventing or treating sars-cov-2 infections
US20040097473A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
US20040092532A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
WO2023212718A2 (fr) Procédés de traitement d'une infection virale et procédés d'inhibition de réplication virale
JPWO2003000668A1 (ja) オキサ（チア）ゾリジン化合物、製造法および抗炎症薬
Castro et al. TDZD's: Selective and ATP Noncompetitive Glycogen Synthase Kinase 3 Inhibitors
KR20050034760A (ko) 선택적 포스포디에스테라제-4 억제제에 의한 비알레르기성비염의 치료방법

Legal Events

Date Code Title Description
FZDE Discontinued